Anti-CD40L mAb alone or in combination with sirolimus or CsA results in low levels of donor engraftment in nonirradiated mice
| Reagent . | No. chimeric . | % donor . | Range . |
|---|---|---|---|
| BM 80 (day 0)3-150 | |||
| Hamster IgG | 1/15 | 0 ± 0 | 3 |
| Anti-CD40L | 7/103-151 | 4 ± 33-151 | 4 -8 |
| Anti-CD40L + sirolimus | 20/203-151,3-152 | 8 ± 23-151,3-152 | 6 -15 |
| Anti-CD40L + CsA | 9/103-151 | 7 ± 33-151 | 3 -11 |
| Sirolimus + CsA | 3/9 | 2 ± 3 | 3 -8 |
| BM 40 (day 0, 14) | |||
| Anti-CD40L | 6/10 | 5 ± 4 | 6 -13 |
| Sirolimus | 0/103-152 | 0 ± 03-152 | NA |
| CsA | 0/103-152 | 0 ± 03-152 | NA |
| Anti-CD40L + sirolimus | 10/103-152 | 10 ± 23-152 | 8 -14 |
| Anti-CD40L + CsA | 10/103-152 | 8 ± 4 | 5 -16 |
| Reagent . | No. chimeric . | % donor . | Range . |
|---|---|---|---|
| BM 80 (day 0)3-150 | |||
| Hamster IgG | 1/15 | 0 ± 0 | 3 |
| Anti-CD40L | 7/103-151 | 4 ± 33-151 | 4 -8 |
| Anti-CD40L + sirolimus | 20/203-151,3-152 | 8 ± 23-151,3-152 | 6 -15 |
| Anti-CD40L + CsA | 9/103-151 | 7 ± 33-151 | 3 -11 |
| Sirolimus + CsA | 3/9 | 2 ± 3 | 3 -8 |
| BM 40 (day 0, 14) | |||
| Anti-CD40L | 6/10 | 5 ± 4 | 6 -13 |
| Sirolimus | 0/103-152 | 0 ± 03-152 | NA |
| CsA | 0/103-152 | 0 ± 03-152 | NA |
| Anti-CD40L + sirolimus | 10/103-152 | 10 ± 23-152 | 8 -14 |
| Anti-CD40L + CsA | 10/103-152 | 8 ± 4 | 5 -16 |
Nonirradiated B6 mice were infused with 80 × 106 BALB/c BM on day 0 or 40 × 106 BALB/c BM on days 0 and 14 as indicated. Reagents were administered from day − 1 through day 14. PBLs were typed for percentage donor-host at 3.5 months after BMT. Chimeric is defined as more than 3% donor PBLs. Percentage donor is defined as average percentage of donor cells of all mice in the group ± 1 SD. Range indicates lowest to highest level of percentage donor cells in engrafted mice. NA indicates not applicable.
Refers to BM cell dose (× 106) and day(s) of BM administration.
P < .001 compared with hamster IgG for BM administered only on day 0.
P ≤ .004 compared with anti-CD40L as a single agent.